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Abstract
Purpose: We perform quality assurance (QA) for indirect dynamic tumor tracking(DTT) using four-dimensional radiation therapy (the Vero4DRT™ system).
Methods: A single photon beam was set with a 40 × 40 mm2 field size at a gantryangle of zero degrees and a low monitor unit setting of 200. Doses were measuredusing a 0.016 cm3 ionization chamber inserted in a phantom under stationary, DTT,and non-DTT conditions for sinusoidal (peak-to-peak) amplitude [A] and breathingperiod [T] (20 mm, 2 s; 20 mm, 4 s; and 40 mm, 4 s). The stationary condition wasmeasured for comparison. Dose profiles were measured using Gafchromic EBT3films in the phantom under the same conditions. Results: For chambermeasurement, the relative doses were as follows: 0.99 with non-DTT and 1.00 withDTT at A = 20 mm and T = 2 s; 0.99 with non-DTT and 1.00 with DTT at A = 20 mmand T = 4 s; and 0.84 with non-DTT and 1.00 with DTT at A = 40 mm and T = 4 s.For film measurement, the spatial distances between the 90% dose of the doseprofiles were as follows: 6.53 mm for non-DTT and 0.40 mm for DTT at A = 20 mmand T = 2 s; 6.33 mm for non-DTT and 0.15 mm for DTT at A = 20 mm and T = 4 s;and 10.61 mm for non-DTT and 0.17 mm with DTT at A = 40 mm and T = 4 s.
Conclusion: Our results showed high dosimetric and geometric accuracy for DTTusing four-dimensional modeling and marked reduction of the blurring effects ondose distribution. We recommend the use of a QA procedure for DTT performedusing the Vero4DRT™ system.
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1. IntroductionThrough breathing management, stereotactic bodyradiation therapy (SBRT) can deliver increased doses ofradiation to tumors while decreasing the dose deliveredto normal tissue.1-3 Several methods for controllingrespiratory motion have been reported, including breathholding4, respiratory gating5, and dynamic tumortracking (DTT).6-8 Breath holding is more difficult forpatients who cannot repeatedly hold their breath overthe delivery time. Respiratory gating needs a longertreatment time to deliver the dose within a particularportion of the patient’s breathing cycle. Therefore,neither of these methods is ideal. In contrast, DTT is aninnovative technique that does not require either alonger treatment time or the burden of breath holding.6-8DTT can be categorized into direct and indirect methods.The Vero4DRT™ system is a four-dimensional (4D)
radiation therapy that uses indirect DTT approacheswith external signals in consideration of the risksassociated with the increased radiation dose deliveredby Kilovoltage (kV) X-ray imaging. The DTT techniquesof the Vero4DRT™ system require synchronization of thegimbals swing with the patient’s respiratory cycle, whichis based on 4D modeling. Several investigators havereported the tracking accuracy of DTT in theVero4DRT™ system using chamber and filmmeasurement.6-7 The American Association of Physicistsin Medicine (AAPM) Task Group (TG) 76 reported on thequality assurance (QA) of all respiratory techniques.9The AAPM-TG 142 also recommended monthly andannual tolerance and function checks for respiratorygating.10 However, the tolerance values have not beenstated because DTT technique was rarely used in 2009.
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In this study, we assessed the chamber and filmmeasurements to confirm tracking accuracy by acomparison with the non-DTT results. We alsocalculated the 4D-modeling error between the predictedand detected target motions. Finally, we comparedwhether the 4D-modeling-error and measurementresults were correlated.
2. Methods and Materials
2.1 Vero4DRT systemWe perform QA for indirect DTT using the Vero4DRT™system in our institution. The Vero4DRT™ system(MHI-TM2000; Mitsubishi Heavy Industries, Ltd., Tokyo,Japan, and Brainlab, Feldkichen, Germany) is describedelsewhere.6-8 Gimbaled X-ray head mounted on anO-ring gantry with a C-band klystron, a system-specificfixed jaw, and a multileaf collimator (MLC). Thegimbaled X-ray head can swing along two orthogonalaxes up to ± 2.5° (swings the beam up to ± 41.9 mm ineach direction on the isocenter plane), allowing pan andtilt motion of the linac. The Vero4DRT™ system uses afully integrated target-positioning concept, an ExacTracsystem version 3.5.3 (BrainLAB AG, Feldkirchen,Germany) automated infrared (IR) camera mounted onthe ceiling of the treatment room, and two orthogonalkV X-ray imaging systems attached to the O-ring at 45°from the MV beam axis. The kV X-ray imaging systemsacquire cone-beam computed tomography (CBCT) datausing the O-ring rotation.
2.2 Experimental procedureIn Figure 1, the entire phantom system can be seen. Theprogrammable respiratory motion table (CIRS. Inc.,Norfolk, VA, USA) was used to simulate breathing-induced organ motion. The dynamic phantom wascapable of motion based on an arbitrary input function,and the motion table had one table that moved in thehorizontal direction and one that moved in the verticaldirection (the motions of these tables were
synchronized). We used iron markers as substitutes forgold ones. Two iron markers, each with a diameter of 2.0mm, were attached to the phantom surfaces; at least twomarkers were required for establishing 4D modelingfunction. The center of the phantom was set at theisocenter of the motion table that moved in thehorizontal direction. An IR phantom was positioned onthe vertical direction motion table as a surrogate signal.4D modeling with the Vero4DRT™ system is describedelsewhere.11-12 Briefly, two iron markers on the cubephantom and the IR markers on the vertical table aresimultaneously acquired to calculate the 4D modelingfunction. A pair of orthogonal kV X-rays at gantry anglesof 0° and 90° acquired the positions of the iron markersevery 320 or 640 ms. The sampling interval of the kVX-ray images automatically changed to 640 ms when thevelocity of the IR marker motion decreased. Theacquisition times ranged from 20 to 40 s. The center ofthe two markers during motion was defined as thedetected target position. The motion of the surrogatewas acquired from the IR markers attached on thephantom monitored by the IR camera on the ceiling ofthe treatment room every 16.7 ms. The 4D modelingfunction was a quadratic function of the IR markerposition and velocity,= + + + + ,where, Ppredict is the predicted target position, PIR is the IRmarker positions and vIR is the vertical velocity of the IRmarkers. Parameters a, b, c, d, and e were optimized byminimizing the residual errors between Ppredict and thepredicted target position for each IR marker. Afteranalyzing the 4D motion data of the target and IRmarker motions, the 4D modeling function wascalculated by the ExacTrac system. The target positioncalculated by the 4D modeling function was defined asthe predicted target position.
Figure 1: (a) Experimental setup for a single field. The phantom was placed on the motion table. Then, the chamber and filmwere inserted in the phantoms. (b) Two iron markers were attached to the phantom’s surface (red circle).
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The iPlan RT DoseTM treatment planning system version4.5.3 (BrainLAB, Feldkirchen, Germany) was used forplan design. A single photon beam was set with a 40 ×40-mm2 field size at a gantry angle of zero degrees and alow monitor unit setting of 200 as the reference in theDTT accuracy comparisons. Sinusoidal motionsequences were produced in the dynamic phantom,using different amplitudes and breathing period. Toinvestigate correlation between the 4D modeling errorand the tracking accuracy, we performed the followingpeak-to-peak amplitudes (A) and breathing period (T)assessments: 1D sinusoidal patterns (A, T) = (20 mm, 2s), (20 mm, 4 s), and (40 mm, 4 s) and a volunteer’srespiratory pattern (20 mm, average of 4 s) in thecranio-caudal (CC) direction. IR marker motion wasfixed at a peak-to-peak amplitude of 20 mm and thebreathing period was synchronized with the targetmotion. Irradiation fields were then delivered underthree conditions: with the phantom moving and DTTbased on the motion of the phantom, with the phantommoving but with non-DTT, and with a stationaryphantom (for comparison).Dose outputs were measured using a 0.016 cm3ionization chamber (PTW31016 pinpoint chamber;PTW, GmbH, Freiburg, Germany) in the center ofphantom. Dose values were relative to the dosemeasured for a static beam with stationary phantom.Gafchromic EBT3 films (International Specialty ProductsCorporation, Wayne, NJ, USA) were inserted in thephantom and irradiated under the same conditions asthose for the chamber measurement. An EpsonExpression ES-G11000 (Epson Seiko Corporation,Nagano, Japan) document scanner was turned on 30 minbefore scanning to allow it to warm up sufficiently andprevent temperature-dependent response effects.Analysis of the scanned images was performed with theDD-System (R-TECH, Inc., Tokyo, Japan). The doseprofiles of all films were normalized to the central axisdose. We compared the dose profile between the 90%dose of the dose profile for DTT and the stationaryphantom to evaluate geometric accuracy.13The differences between detected and predictedpositions of the iron markers were defined as the 4Dmodeling error. The mean (μ) and standard deviation(SD) of the absolute 4D modeling function error wereanalyzed. The 95th percentile of the 4D modeling error(4D-E95%) between the detected and predicted targetposition (μ + 2SD) was calculated to compare each 4Dmodeling error.
3. Results
3.1 Chamber measurementThe chamber results summarized in Table 1 indicatedexperimental certainty for the DTT measurements. For1D sinusoidal pattern, the relative doses were as
follows: 0.99 with non-DTT and 1.00 with DTT at A = 20mm and T = 2 s; 0.99 with non-DTT and 1.00 with DTT at
A = 20 mm and T = 4 s; and 0.84 with non-DTT and 1.00with DTT at A = 40 mm and T = 4 s. For the volunteer’srespiratory pattern, the relative doses were 1.00 fornon-DTT and 1.00 with DTT. The largest deviationoccurred when the larger peak-to-peak amplitude wasdelivered with non-DTT.
Table 1: Chamber measurement results.Amplitude(mm) Breathing period(s) Relative dosenon-DTT DTT20 2 0.99 1.0020 4 0.99 1.0040 4 0.84 1.00Volunteer’s respiratory 1.00 1.00Chamber measurements were performed understationary, dynamic tumor tracking (DTT), and non-DTTconditions with sinusoidal patterns (amplitude andbreathing period) and a volunteer’s respiratory pattern,in the cranio-caudal direction. Dose values are relativeto the dose measured in the stationary phantom.
3.2 Film measurementFigure 2 shows the film measurement results for thestationary phantom, DTT, and non-DTT at A = 40 mmand T = 4 s. The stationary phantom and DTT had almostthe same dose distribution, while non-DTT increased theblurring effects of the dose distribution. Figure 3 showsthe dose profiles for the stationary phantom, DTT, andnon-DTT for sinusoidal and volunteer’s respiratorypatterns. DTT reduced the blurring effects and produceda dose profile curve similar to that of the stationaryphantom.The film results are summarized in Table 2. Comparedwith the stationary conditions, the spatial distancebetween the 90% dose of the dose profiles were asfollows: 6.53 mm for non-DTT and 0.40 mm for DTT at A= 20 mm and T = 2 s; 6.33 mm for non-DTT and 0.15 mmfor DTT at A = 20 mm and T = 4 s; and 10.61 mm fornon-DTT and 0.17 mm for DTT at A = 40 mm and T = 4 s.For the volunteer’s respiratory pattern, the dose profileswere 6.02 mm (left side: 4.67 mm, right side: 7.37 mm)for non-DTT and 0.25 mm for DTT. The largest deviationoccurred when the larger peak-to-peak amplitude wasdelivered with non-DTT.
Table 2: Film measurement results.Amplitude(mm) Breathingperiod (s) E90% (mm)non-DTT DTT20 2 6.53 0.4020 4 6.33 0.1540 4 10.61 0.17Volunteer’s respiratory 6.02 0.25Film measurements were performed under stationary,dynamic tumor tracking (DTT), and non-DTT conditions,
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with sinusoidal patterns (amplitude and breathingperiod) and a volunteer’s respiratory pattern, in thecranio-caudal direction. Dose values are relative to thedose measured in the stationary phantom. E90% =
distance of 90% dose profile between stationary andDTT or non-DTT conditions.
Figure 2: A single field for the one-dimensional sinusoidal pattern with an amplitude of 40 mm and a breathing period of 4 sunder (a) stationary, (b) dynamic tumor tracking (DTT), and (c) non-DTT conditions. DTT clearly reduced the blurring, whichwas comparable to that produced by static dose distribution.
Figure 3: The dose profiles for stationary (blue line), dynamic tumor tracking (DTT; red line), and non-DTT (green line)conditions under different sinusoidal patterns (amplitude and period): (a) 20 mm, 2 s; (b) 20 mm, 4 s; (c) 40 mm, 4 s; and (d)the volunteer’s respiratory pattern.
3.3 4D-modeling errorFigure 4 shows the graph of predicted and detectedtarget motion in the 4D modeling. As shown, the4D-modeling error was greatest at the “end-inspiration”and “end-expiration” phases in particular (amplitude, 20mm; breathing period, 2 s).
The 4D-modeling error results are summarized in Table3. The largest 4D-E95% occurred with an amplitude of 20mm and a breathing period of 2 s. For 1D-sinusoidalpatterns, the 4D-E95% values were 1.47 mm (A = 20 mm,
T = 2 s), 0.38 mm (A = 20 mm, T = 4 s), and 0.72 mm (A =40 mm, T = 4 s). For the volunteer’s respiratory pattern,the 4D-E95% was 0.34 mm.
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Figure 4: Graphs of detected (blue line) and predicted (red line) target motions for different sinusoidal patterns (amplitudeand breathing period): (a) 20 mm, 2 s; (b) 20 mm, 4 s; (c) 40 mm, 4 s; and (d) the volunteer’s respiratory pattern.
3.4 Comparison of the 4D-modeling and film
measurement dataThe results for 4D-E95% and film measurement with DTTof both sinusoidal and the volunteer’s respiratorypatterns are summarized in Table 3. A good correlationwas found between the 4D-E95% and the filmmeasurement results (R2 = 0.70).
Table 3: The 95th percentile of the 4D-modeling error(4D-E95%) and film measurement result under dynamictumor tracking for 1D sinusoidal patterns.Amplitude(mm) Breathing period(s) 4D-E95%(mm) Film result(mm)20 2 1.47 0.4020 4 0.38 0.1540 4 0.72 0.17Volunteer’s respiratory 0.34 0.25Results are for 1D sinusoidal pattern (amplitude andbreathing period) and a volunteer’s respiratory pattern,in the cranio-caudal direction. 4D-E95% = 4D- modelingerror between the detected and predicted targetposition (μ + 2SD).
4. DiscussionThe AAPM-TG142 recommends the examination ofrespiratory-gated accelerator operation, measurementof beam energy and output constancy, and measurementof the temporal accuracy of phase/amplitude gatingwindows; but it provides no details regarding theperformance of these examinations.10 Recently, woods et
al. reported detailed and comprehensive guidance forrespiratory gating commissioning and routine QA in
accordance with AAPM - TG142.14 As for real-timetumor-tracking radiotherapy systems, Shiinoki et al.suggested a QA procedure for respiratory-gatedradiation that reduced the blurring effects on dosedistribution with high dosimetric and geometricaccuracy.13 However, there are no existing proceduralguidelines specifically for DTT. It is important that theaccuracy of DTT be measured prior to treatment.In this study, the gimbals head was swung to a maximumangle of 1.2 degrees, which produced a distance betweenthe target and radiation source of 100.02 cm. At thisangle, the beam path hardly changed from that at thezero-degree angle. Therefore, the relative dose was 1.00for DTT in a single 40 × 40 mm field. For non-DTT,motion caused blurring of the dose profile that causedan increased beam penumbra. In contrast, DTTdramatically reduced the blurring dose profile andproduced a penumbra that was similar to that of thestationary phantom. The volunteer’s respiratory patternreflected the motion probability density function.15The 4D-modeling error was increased on the targetmotion amplitude, and the peak position sometimesoverestimated the predicted position. Largest 4D-E95%was occurred under rapidly breathing pattern, becauseX-ray imaging with 320 or 640 ms cannot detect ironmarkers at the “end-inspiration” and “end-expiration”phases. Thereby, slight blurring was generated on the90% dose profile. However, the 4D-modeling error maybe predicted by mechanical errors in DTT. Mukumoto et
al. reported that positional tracking errors correlatedstrongly with 4D-modeling errors, which resulted frommiscorrelations between target and IR marker motions.6
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In the moving phantom study, the correlation between4D-modeling and film dosimetric errors was very smallbecause the motions of the target and the infraredmarkers were perfectly synchronized. The sinusoidalpattern is easily reproducible and predictable.A limitation of this study was that it was performedunder 1D sinusoidal regulated moving target in the CCdirection only. Further studies should examine thecorrelation between 4D modeling and tracking accuracyunder various conditions and in different directions.
5. ConclusionOur present results indicate the high dosimetric andgeometric accuracy of DTT when using 4D modeling andthat its use dramatically reduced the blurring effects ondose distribution when compared with those withnon-DTT. We recommend the use of a QA procedure forDTT performed with the Vero4DRT™ system.
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